In:
Pharmacogenomics, Future Medicine Ltd, Vol. 12, No. 9 ( 2011-09), p. 1281-1291
Kurzfassung:
Aim: Recently a SNP of the gene encoding P450 oxidoreductase (POR*28; rs1057868C 〉 T) has been associated with increased in vivo CYP3A activity using midazolam as a drug probe. Because tacrolimus is metabolized by CYP3A isoenzymes, this SNP might affect tacrolimus pharmacokinetics. Materials & methods: To test this hypothesis we performed a study in a cohort of 298 de novo renal allograft recipients stratified according to CYP3A5 genotype, which has a known impact on tacrolimus pharmacokinetics. Results: We found that in CYP3A5 expressers (CYP3A5*1 allele carriers) receiving a standard loading dose of 0.2 mg/kg, POR*28T allele carriers had lower tacrolimus C 0 levels in the first days post-transplantation and reached target C 0 levels significantly later as compared with POR*28CC homozygous patients. The POR*28T allele carriers had significantly higher tacrolimus dose requirements throughout the first year. In CYP3A5 nonexpressers (CYP3A5*3/*3) the POR*28 SNP did not affect tacrolimus pharmacokinetics. Conclusion: These data indicate that the POR*28 SNP is associated with additional increases in early tacrolimus dose-requirements in patients carrying a CYP3A5*1 allele. Original submitted 22 April 2011; Revision submitted 28 May 2011
Materialart:
Online-Ressource
ISSN:
1462-2416
,
1744-8042
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2011
SSG:
15,3
